Skip to content
Bomb Report – Lifestyle
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
April 13, 2026
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 13, 2026
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
March 6, 2026
←
Previous Page
1
2